Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.59 HKD | -2.34% | -8.84% | -39.38% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.38% | 464.3Cr | - | ||
+49.52% | 5.67TCr | B- | ||
-3.05% | 4.1TCr | B | ||
+38.14% | 3.81TCr | A | ||
-11.22% | 2.69TCr | C | ||
+14.89% | 2.56TCr | B- | ||
-22.61% | 1.86TCr | B | ||
+0.10% | 1.24TCr | B+ | ||
+26.60% | 1.2TCr | C+ | ||
+22.35% | 1.19TCr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300759 Stock
- 3759 Stock
- Ratings Pharmaron Beijing Co., Ltd.